Pharmaceutical Resources, Inc.
Distribution agreement with The Generics Group B.V. is expanded to include five additional generic drugs. ANDAs for the five unnamed drugs were submitted by divisions of The Generics Group: the Canadian firm Genpharm and the Australian firm Ameripharm. Patents for three of the five drugs have not yet expired. PRI already is the exclusive U.S. distributor of Genpharm's piroxicam and pindolol. All the products will be marketed under the name of PRI's subsidiary Par or under private label names. Par has not received an ANDA approval since 1989, but PRI expects to be cleared soon under FDA's application integrity policy.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth